Cargando…
Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer
BACKGROUND: Thyroid transcription factor-1 (TTF-1) is expressed in approximately 70% of lung adenocarcinomas and is one of the most reliable makers to distinguish primary lung adenocarcinoma from metastatic disease. TTF-1-negative status is a poor prognostic factor, and TTF-1-negative lung adenocarc...
Autores principales: | Iso, Hirokazu, Hisakane, Kakeru, Mikami, Erika, Suzuki, Takahiro, Matsuki, Satoru, Atsumi, Kenichiro, Nagata, Kohji, Seike, Masahiro, Hirose, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579824/ https://www.ncbi.nlm.nih.gov/pubmed/37854151 http://dx.doi.org/10.21037/tlcr-23-331 |
Ejemplares similares
-
Development of eosinophilic pneumonia from eosinophilic bronchiolitis without asthma: A case report
por: Mikami, Erika, et al.
Publicado: (2023) -
A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report
por: Iso, Hirokazu, et al.
Publicado: (2023) -
Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023) -
TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023) -
Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020)